Ticker Details
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
IPO Date:	January 31, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.35B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.54 | 2.50%
Avg Daily Range (30 D):	$0.52 | 2.46%
Avg Daily Range (90 D):	$0.62 | 2.53%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	1.66M
Avg Daily Volume (90 D):	2.08M

Trade Size
Avg Trade Size (Sh.):	67
Avg Trade Size (Sh.) (30 D):	69
Avg Trade Size (Sh.) (90 D):	72

Institutional Trades
Total Institutional Trades:	7,302
Avg Institutional Trade:	$2.86M
Avg Institutional Trade (30 D):	$4.98M
Avg Institutional Trade (90 D):	$3.69M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.63M
Avg Closing Trade (30 D):	$7.58M
Avg Closing Trade (90 D):	$8.21M
Avg Closing Volume:	90.65K

News

Apr 6, 2026 @ 2:51 PM ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire,... Source: Bragar Eagel & Squire, P.C.

Apr 5, 2026 @ 11:29 PM TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL... Source: Rosen Law Firm

Apr 5, 2026 @ 10:37 PM RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUN... Source: Rosen Law Firm

Apr 1, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx... Source: Bronstein, Gewirtz & Grossman Llc

Apr 1, 2026 @ 2:16 AM Ultragenyx Pharmaceutical Inc. Notice of April 6, ... Source: Kahn Swick & Foti, Llc

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-5.83	$-1.28	$-5.83
Diluted EPS	$-5.83	$-1.28	$-5.83
Revenue	$673M	$207.28M	$673M
Gross Profit
Net Income / Loss	$-575M	$-128.56M	$-575M
Operating Income / Loss	$-535M	$-113.28M	$-535M
Cost of Revenue
Net Cash Flow	$248M	$222.12M	$248M
PE Ratio

Splits
Jan 17, 2014	15:47